Top 10 Biopharma Dealmakers by Upfront Cash

by | Sep 4, 2018

Data from the DealForma database and an analysis were prepared for a story published in Endpoints News looking at top dealmakers in recent biopharma partnerships. We applied certain criteria to filter for deals involving major R&D and commercial rights, namely licensing of biotech, pharmaceutical, medical device, diagnostic, and technology platforms. This gave us an initial set of over 950 deals form January 2017 to August 2018 among the broader set of 12,000+ deals. We then sorted by upfront cash payments, overall deal values, deal counts, and applied our experience in context to produce tables of top companies and their deal totals.

Interesting Takeaways
  • The top 10 companies paid over $6.5 billion of the $11 billion-plus in total upfront cash in the 20 months since the beginning of 2017 – 60% of the total from 10 companies.
  • This was among 131 deals in the group and $51.3 billion in overall deal value
  • We could have added 12 more companies to the list and still see deals with $100 million or more paid up front
DealForma Datasets
  • Companies – Large biopharma companies in-licensing or paying for the option to license
  • Deals – Development and commercialization deals for technology platforms, preclinical and later compounds (Phase I, Phase II, Phase III, and Approved), medical devices, and diagnostics (full list of criteria in the DealForma platform).

Story Published in Endpoints News: Read the story

Want data for your analysis? Want us to do it? Subscribers get both.

Schedule your demo of the DealForma database to see how we help you get better reports done faster.

16,326

Deal Profiles

8,389

Funding Rounds

18,249

Company Profiles

10,337

Product Profiles

119K+

Clinical Trials

3,397

Business Developers

Specifically for Biotech, Pharma, Device, and Diagnostics

More from the DealForma Blog

Biotech Companies in Major Industry Centers Rake in the Cash

Location, Location, Location: Real estate costs a lot in the three largest biotech hubs, but it’s a charm for raising capital. Biotech companies raised $37.4 billion globally in 1027 rounds of venture financing over the past four years from 2015 through the third quarter of 2018 and companies located in the San Francisco Bay Area, greater Boston area, and San Diego County accounted for 55 percent of the total raised and 46 percent of the financing activity.

You met at BIO. Now it's Deal Time.

With thousands of company profiles and a decade of deals specifically in biotech and pharma, you'll take the guesswork out of deal comps. Schedule your customized demo to see how DealForma helps you win that term sheet with better data.

DealForma is the biopharma database providing you comprehensive information and analyst support hours to help you be more confident using quality data in your business development research.

 

Company

About Us

Analysis / Blog

Contact Us

Product

Support

Pricing

Connect

Made in San Mateo, CA and around the world    support@dealforma.com   (650) 353-9363  Terms  Privacy

Copyright © 2019 DealForma

Share This